OTCPK:CGNS.F

Stock Analysis Report

Cognetivity Neurosciences

Executive Summary

Cognetivity Neurosciences Ltd. operates as a healthcare company.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Risks

  • Cognetivity Neurosciences has significant price volatility in the past 3 months.
  • Cognetivity Neurosciences is not covered by any analysts.

Share Price & News

How has Cognetivity Neurosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-11.5%

CGNS.F

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

n/a

CGNS.F

9.9%

US Medical Equipment

0.6%

US Market

No trading data on CGNS.F.

No trading data on CGNS.F.


Share holder returns

CGNS.FIndustryMarket
7 Day-11.5%1.1%-0.6%
30 Day-16.1%0.6%2.2%
90 Day-50.5%2.9%1.1%
1 Yearn/a10.8%9.9%2.9%0.6%
3 Yearn/a70.1%64.9%44.6%35.2%
5 Yearn/a138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is Cognetivity Neurosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cognetivity Neurosciences undervalued based on future cash flows and its price relative to the stock market?

7.51x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Cognetivity Neurosciences to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Cognetivity Neurosciences to establish if it is available at substantial discount.


Price Based on Earnings

Cognetivity Neurosciences is loss making, we can't compare its value to the US Medical Equipment industry average.

Cognetivity Neurosciences is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Cognetivity Neurosciences, we can't assess if its growth is good value.


Price Based on Value of Assets

Cognetivity Neurosciences is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Cognetivity Neurosciences expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cognetivity Neurosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Cognetivity Neurosciences performed over the past 5 years?

-63.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Cognetivity Neurosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Cognetivity Neurosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Cognetivity Neurosciences's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Cognetivity Neurosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Cognetivity Neurosciences has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Cognetivity Neurosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Cognetivity Neurosciences's financial position?


Financial Position Analysis

Cognetivity Neurosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Cognetivity Neurosciences has no long term commitments.


Debt to Equity History and Analysis

Cognetivity Neurosciences has no debt.

Cognetivity Neurosciences currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

Cognetivity Neurosciences has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Cognetivity Neurosciences has less than a year of cash runway based on current free cash flow.

Cognetivity Neurosciences has less than a year of cash runway if free cash flow continues to grow at historical rates of 85.6% each year.


Next Steps

Dividend

What is Cognetivity Neurosciences's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Cognetivity Neurosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Cognetivity Neurosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Cognetivity Neurosciences has not reported any payouts.

Unable to verify if Cognetivity Neurosciences's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Cognetivity Neurosciences has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Cognetivity Neurosciences's salary, the management and board of directors tenure and is there insider trading?

1.8yrs

Average board tenure


CEO

Sina Habibi 0

0yrs

Tenure

0

Dr. Sina Habibi serves as Co-Founder & Chief Executive Officer at Cognetivity Neurosciences Ltd and also serves as its Director since December 21, 2017. 


Board Age and Tenure

1.8yrs

Average Tenure

53yo

Average Age

The average tenure for the Cognetivity Neurosciences board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Denise Lok (35yo)

    CFO & Corporate Secretary

    • Tenure: 0yrs
  • Tom Sawyer (49yo)

    Chief Operating Officer

    • Tenure: 0yrs
  • Sina Habibi

    Co-Founder

    • Tenure: 0yrs
  • Chris Kalafatis

    Chief Medical Officer & Director

    • Tenure: 1.8yrs
  • Mark Phillips

    Chief Compliance Officer & Director

    • Tenure: 1.8yrs
  • Seyed-Mahdi Khaligh-Razavi

    Co-Founder & Chief Scientific Officer

    • Tenure: 0yrs

Board Members

  • Hanspeter Spek (70yo)

    Member of Advisory Board

    • Tenure: 1.2yrs
  • David Velisek (47yo)

    Independent Director

    • Tenure: 3.8yrs
  • Robert, Rob Kang (53yo)

    Independent Director

    • Tenure: 1.8yrs
  • Sina Habibi

    Co-Founder

    • Tenure: 0yrs
  • Chris Kalafatis

    Chief Medical Officer & Director

    • Tenure: 1.8yrs
  • Mark Phillips

    Chief Compliance Officer & Director

    • Tenure: 1.8yrs

Company Information

Cognetivity Neurosciences Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cognetivity Neurosciences Ltd.
  • Ticker: CGNS.F
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$6.422m
  • Listing Market Cap: CA$4.842m
  • Shares outstanding: 45.87m
  • Website: https://www.cognetivity.com

Number of Employees


Location

  • Cognetivity Neurosciences Ltd.
  • 1075 West Georgia Street
  • Suite 1980
  • Vancouver
  • British Columbia
  • V6E 3C9
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CGNCNSX (Canadian National Stock Exchange)YesNew Common SharesCACADMar 2018
1UBDB (Deutsche Boerse AG)YesNew Common SharesDEEURMar 2018
CGNS.FOTCPK (Pink Sheets LLC)YesNew Common SharesUSUSDMar 2018

Biography

Cognetivity Neurosciences Ltd. operates as a healthcare company. It develops integrated cognitive assessment, a cognitive testing platform, which includes visual stimulus based diagnostic test and artifici ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 01:03
End of Day Share Price2019/09/20 00:00
Earnings2019/04/30
Annual Earnings2019/01/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.